Sign in
Taking people in United StatesPhase 1

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Key facts

Who runs it
Rocket Pharmaceuticals Inc.
Where
Durham, La Jolla, and Philadelphia, United StatesSee the 3 sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
9 people, planned
Started
29 Aug 2023
Expected to end
Sept 2029
Type of study
Interventional
Treatments tested
  • RP-A601
Record updated
16 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male or female ≥18 years at the time of signing the informed consent
  • Capable and willing to provide signed informed consent
  • Clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
  • Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
  • History of Implantable Cardioverter-Defibrillator (ICD) implantation ≥6 months prior to enrollment
  • PVC frequency ≥500 per 24 hours by ambulatory rhythm monitoring
  • Left ventricular ejection fraction by echocardiogram or CMR ≥50%

Who cannot take part

  • Anti-AAVrh.74 capsid neutralizing antibody titer of >1:40
  • Previous participation in a study of gene transfer or gene editing
  • New York Heart Association (NYHA) Class IV heart failure
  • Cardiomyopathy related to a genetic etiology other than PKP2 truncating variant
  • Severe Right Ventricular (RV) dysfunction

This trial is currently available in United States.

  • Duke UniversityDurham, United StatesContact: Meghan Pergola, MPHTaking people
  • University of California San DiegoLa Jolla, United StatesContact: Barry Greenberg, MDTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part

About the trial

What the trial wants to find out

This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.

The group in the trial

  • RP-A601Treatment being tested

    Single ascending dose of RP-A601 in 2 consecutive cohorts

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM)
Publications
Record updated
16 April 2026